Search

Leonard G. Gomella, MD, FACS, hailed precision medicine's transformative influence on prostate cancer in a presentation during the New York GU[TM] 17th Annual Interdisciplinary Prostate Cancer Congress[R] and Other Genitourinary [...]

Treatment with axicabtagene ciloleucel (axi-cel; Yescarta) induced high rates of durable responses in patients with indolent non-Hodgkin lymphoma (NHL), according to extended follow-up results of the ZUMA-5 trial that were [...]

Selinexor (Xpovio) demonstrated a clinical benefit in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) across age groups, according to results of a post hoc analysis of the SADAL trial [...]

Treatment with GP2 immunotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) led to a 100% disease-free survival (DFS) rate for patients with HER2 3+ disease who received adjuvant trastuzumab (Herceptin), according to [...]